Pacira BioSciences, Inc. (PCRX)
NASDAQ
Market Cap
$1.29B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
699 of 809
Rank in Industry
41 of 53
Largest Insider Buys in Sector
PCRX Stock Price History Chart
PCRX Stock Performance
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Insider Activity of Pacira BioSciences, Inc.
Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $0 and sold $4.22M worth of Pacira BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $91,250 and sold $18.47M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,500 shares for transaction amount of $91,250 was made by WINSTON ROY (Chief Clinical Officer) on 2020‑03‑11.
List of Insider Buy and Sell Transactions, Pacira BioSciences, Inc.
| 2024-06-13 | Sale | GAUGLER DARYL | Chief Operating Officer | 1,000 0.0021% | $28.38 | $28,380 | -0.63% | |
| 2024-06-13 | Sale | WILLIAMS KRISTEN | Chief Administrative Officer | 7,452 0.0157% | $28.38 | $211,488 | -0.63% | |
| 2024-06-13 | Sale | HASTINGS PAUL J | director | 880 0.0019% | $28.38 | $24,974 | -0.63% | |
| 2024-06-12 | Sale | RIKER LAUREN | Senior Vice President, Finance | 3,970 0.0085% | $28.72 | $114,018 | -1.39% | |
| 2024-06-11 | Sale | SLONIN JONATHAN | Chief Medical Officer | 5,012 0.0106% | $28.57 | $143,193 | -2.07% | |
| 2024-03-08 | Sale | PACE GARY W | director | 90,000 0.1889% | $30.60 | $2.75M | -7.96% | |
| 2024-03-07 | Sale | PACE GARY W | director | 28,257 0.0613% | $30.81 | $870,598 | -5.48% | |
| 2024-03-06 | Sale | PACE GARY W | director | 1,066 0.0023% | $29.67 | $31,628 | -3.69% | |
| 2023-08-02 | Sale | WINSTON ROY | Chief Medical Officer | 509 0.0011% | $34.88 | $17,751 | -18.66% | |
| 2023-07-05 | Sale | Riker Lauren Bullaro | Senior Vice President, Finance | 643 0.0014% | $38.91 | $25,019 | -22.50% | |
| 2023-06-14 | Sale | Williams Kristen Marie | Chief Administrative Officer | 6,467 0.0135% | $37.03 | $239,473 | -21.58% | |
| 2023-06-14 | Sale | Riker Lauren Bullaro | Senior Vice President, Finance | 6,366 0.0137% | $38.42 | $244,606 | -21.58% | |
| 2023-06-08 | Sale | Kronenfeld Mark A. | director | 15,000 0.0327% | $37.04 | $555,600 | -17.48% | |
| 2023-06-07 | Sale | STACK DAVID M | CEO and Chairman | 5,326 0.0117% | $37.87 | $201,669 | -18.62% | |
| 2023-06-07 | Sale | WINSTON ROY | Chief Medical Officer | 1,857 0.0041% | $37.87 | $70,315 | -18.62% | |
| 2023-06-07 | Sale | McLoughlin Dennis | Chief Customer Officer | 1,057 0.0023% | $37.87 | $40,023 | -18.62% | |
| 2023-06-07 | Sale | SLONIN JONATHAN | Chief Clinical Officer | 490 0.0011% | $37.87 | $18,554 | -18.62% | |
| 2023-06-07 | Sale | Reinhart Charles A. III | Chief Financial Officer | 1,371 0.003% | $37.87 | $51,913 | -18.62% | |
| 2023-06-07 | Sale | Ellis Ronald J. Jr. | Chief Strategy Officer | 1,162 0.0026% | $37.87 | $43,999 | -18.62% | |
| 2023-06-07 | Sale | REINHARDT MAX | President, Rest of World | 1,099 0.0024% | $37.87 | $41,614 | -18.62% |
Insider Historical Profitability
22.98%
| PACE GARY W | director | 22127 0.3008% | $27.61 | 5 | 6 | +11.64% |
| WILLIAMS KRISTEN | Chief Administrative Officer | 102912 0.2211% | $27.61 | 0 | 31 | |
| WINSTON ROY | Chief Medical Officer | 52440 0.1129% | $27.61 | 1 | 9 | +64.83% |
| RIKER LAUREN | Senior Vice President, Finance | 38075 0.0818% | $27.61 | 0 | 40 | |
| SLONIN JONATHAN | Chief Clinical Officer | 44569 0.0782% | $27.61 | 0 | 5 | |
| GAUGLER DARYL | Chief Operating Officer | 116040 0.0464% | $27.61 | 0 | 6 | |
| HASTINGS PAUL J | director | 12724 0.0142% | $27.61 | 1 | 18 | +79.52% |
| GORDON CARL L | director | 2828941 6.0919% | $27.61 | 1 | 0 | +33.11% |
| KAILIAN VAUGHN M | 2790479 6.0091% | $27.61 | 3 | 1 | +45.51% | |
| MPM BioVentures IV QP LP | 2790479 6.0091% | $27.61 | 3 | 1 | +45.51% | |
| ORBIMED ADVISORS LLC | 10 percent owner | 2446000 5.2673% | $27.61 | 1 | 9 | +33.11% |
| HBM Healthcare Investments (Cayman) Ltd. | 10 percent owner | 2233993 4.8107% | $27.61 | 2 | 6 | +43.57% |
| Wicki Andreas | director | 451324 0.9719% | $27.61 | 2 | 72 | +43.57% |
| Sanderling Venture Partners VI LP | director | 416083 0.896% | $27.61 | 1 | 5 | +33.11% |
| STACK DAVID M | CEO and Chairman | 153781 0.3312% | $27.61 | 1 | 45 | +35.49% |
| McLoughlin Dennis | Chief Customer Officer | 38115 0.0821% | $27.61 | 0 | 7 | |
| Reinhart Charles A. III | Chief Financial Officer | 33626 0.0724% | $27.61 | 0 | 7 | |
| Ellis Ronald J. Jr. | Chief Strategy Officer | 30909 0.0666% | $27.61 | 0 | 2 | |
| REINHARDT MAX | President, Rest of World | 29225 0.0629% | $27.61 | 0 | 12 | |
| LARANJEIRA CHARLES ANTHONY | Chief Technical Officer | 25852 0.0557% | $27.61 | 0 | 6 | |
| Scibetta James S | President | 25118 0.0541% | $27.61 | 2 | 13 | +5.63% |
| Manning Donald C. | Chief Medical Officer | 23520 0.0506% | $27.61 | 0 | 2 | |
| LONGENECKER JOHN P PHD | 18823 0.0405% | $27.61 | 1 | 12 | <0.0001% | |
| Kronenfeld Mark A. | director | 17897 0.0385% | $27.61 | 5 | 2 | +14.69% |
| Jones James B | SVP & Chief Medical Officer | 16823 0.0362% | $27.61 | 2 | 2 | <0.0001% |
| Scranton Richard | Chief Scientific Officer | 16061 0.0346% | $27.61 | 0 | 5 | |
| MOLLOY ANTHONY | Chief Lgl & Compliance Officer | 12877 0.0277% | $27.61 | 0 | 7 | |
| Braunstein Scott | SVP, Strategy & Corp. Dev. | 9982 0.0215% | $27.61 | 1 | 1 | <0.0001% |
| Brege Laura | director | 9547 0.0206% | $27.61 | 0 | 6 | |
| Weiland Robert J. | Chief Commercial Officer | 5088 0.011% | $27.61 | 0 | 1 | |
| Froimson Mark | 4908 0.0106% | $27.61 | 1 | 2 | <0.0001% | |
| WINGER DENNIS L | director | 2645 0.0057% | $27.61 | 1 | 0 | <0.0001% |
| Markvicka Taunia | SVP, Chief Commercial Officer | 230 0.0005% | $27.61 | 1 | 4 | <0.0001% |
| EVNIN LUKE | director | 0 0% | $27.61 | 3 | 15 | +45.51% |
| PATOU GARY | Chief Medical Officer | 0 0% | $27.61 | 0 | 9 | |
| Pratt John | General Manager, San Diego | 0 0% | $27.61 | 0 | 5 | |
| MIDDLETON FRED A | director | 0 0% | $27.61 | 2 | 5 | +43.57% |
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
| BlackRock | $230.99M | 16.98 | 7.91M | -2.58% | -$6.11M | 0.01 | |
| The Vanguard Group | $149.41M | 10.99 | 5.11M | +0.29% | +$437,131.20 | <0.01 | |
| Frontier Capital Management Co | $55.94M | 4.11 | 1.91M | -8.16% | -$4.97M | 0.52 | |
| State Street | $55.62M | 4.09 | 1.9M | -1.68% | -$950,994.13 | <0.01 | |
| Renaissance Technologies | $55M | 4.04 | 1.88M | +9.64% | +$4.84M | 0.09 | |
| Dimensional Fund Advisors | $47.6M | 3.5 | 1.63M | +15.4% | +$6.35M | 0.01 | |
| Pacer Advisors Inc | $45.95M | 3.38 | 1.57M | +50.98% | +$15.52M | 0.12 | |
| Macquarie Group | $45.61M | 3.35 | 1.56M | +12.78% | +$5.17M | 0.04 | |
| Stephens Investment Management Group LLC | $41.69M | 3.07 | 1.43M | +8.25% | +$3.18M | 0.56 | |
| ClearBridge Investments | $34.25M | 2.52 | 1.17M | +2.31% | +$773,248.68 | 0.03 | |
| ROCK SPRINGS CAPITAL MANAGEMENT, LP | $30.84M | 2.27 | 1.06M | 0% | +$0 | 0.79 | |
| Rice Hall James & Associates, LLC | $30.49M | 2.24 | 1.04M | +0.73% | +$221,224.62 | 1.84 | |
| Geode Capital Management | $30.3M | 2.23 | 1.04M | +3.29% | +$966,281.39 | <0.01 | |
| Baillie Gifford Co | $29.24M | 2.15 | 1M | -5.88% | -$1.83M | 0.02 | |
| Marshall Wace | $23.71M | 1.74 | 811,352 | +68.96% | +$9.68M | 0.03 | |
| Morgan Stanley | $19.59M | 1.44 | 670,327 | -2.19% | -$438,504.56 | <0.01 | |
| Schroder Investment Management Group | $17.68M | 1.3 | 605,151 | -2.66% | -$483,824.75 | 0.02 | |
| Janus Henderson | $17.59M | 1.29 | 602,060 | -0.33% | -$57,649.53 | 0.01 | |
| Bank of America | $17.51M | 1.29 | 599,399 | +31.67% | +$4.21M | <0.01 | |
| Nuveen | $16.56M | 1.22 | 566,713 | +214.53% | +$11.29M | 0.01 | |
| Invesco | $16.09M | 1.18 | 550,659 | +14.82% | +$2.08M | <0.01 | |
| Gagnon Securities | $16.04M | 1.18 | 548,968 | +0.62% | +$99,026.58 | 3.99 | |
| Standard Life | $15.92M | 1.17 | 544,918 | +21.45% | +$2.81M | 0.03 | |
| Archon Capital Management Llc | $15.68M | 1.15 | 536,525 | New | +$15.68M | 0.35 | |
| Northern Trust | $14.92M | 1.1 | 510,745 | -3.32% | -$511,817.49 | <0.01 | |
| Ardsley Advisory Partners | $14.42M | 1.06 | 493,400 | +63.38% | +$5.59M | 2.09 | |
| Charles Schwab | $12.1M | 0.89 | 414,151 | +11.43% | +$1.24M | <0.01 | |
| BNY Mellon | $11.63M | 0.86 | 397,861 | -6.43% | -$799,400.46 | <0.01 | |
| Loomis, Sayles & Company | $11.06M | 0.81 | 378,633 | +15.86% | +$1.51M | 0.02 | |
| Glenmede | $10.62M | 0.78 | 363,405 | +7.84% | +$771,817.00 | 0.05 | |
| T. Rowe Price | $9.7M | 0.71 | 332,020 | -17.77% | -$2.1M | <0.01 | |
| Deutsche Bank | $9.05M | 0.67 | 309,721 | +0.63% | +$56,891.34 | <0.01 | |
| Wellington Management Company | $8.57M | 0.63 | 293,232 | -10.49% | -$1M | <0.01 | |
| Impax Asset Management Group | $7.6M | 0.56 | 260,027 | +30% | +$1.75M | 0.03 | |
| Tributary Capital Management | $7.33M | 0.54 | 250,868 | +3.66% | +$258,976.86 | 0.61 | |
| D. E. Shaw & Co. | $7.03M | 0.52 | 240,439 | +16.71% | +$1.01M | 0.01 | |
| Goldman Sachs | $6.34M | 0.47 | 216,954 | +6.84% | +$406,158.01 | <0.01 | |
| Ameriprise Financial | $6.02M | 0.44 | 206,012 | -4.01% | -$251,788.76 | <0.01 | |
| Assenagon Asset Management S.A. | $5.74M | 0.42 | 196,295 | -20.41% | -$1.47M | 0.02 | |
| Voloridge Investment Management, LLC | $5.51M | 0.41 | 188,444 | +153.1% | +$3.33M | 0.01 | |
| Jane Street Capital | $5.48M | 0.4 | 187,531 | +1,780.2% | +$5.19M | 0.01 | |
| Candriam S C A | $5.32M | 0.39 | 181,901 | -5.21% | -$292,199.99 | 0.03 | |
| UBS | $4.83M | 0.36 | 165,461 | +31.75% | +$1.17M | <0.01 | |
| Nicholas Company Inc | $4.51M | 0.33 | 154,330 | 0% | +$0 | 0.08 | |
| Neumeier Poma Investment Counsel LLC | $4.44M | 0.33 | 151,810 | -9.19% | -$448,819.18 | 0.42 | |
| RhumbLine Advisers | $4.37M | 0.32 | 149,598 | +0.47% | +$20,249.36 | <0.01 | |
| Hillsdale Investment Management Inc. | $4.25M | 0.31 | 145,400 | +8.51% | +$333,108.00 | 0.35 | |
| Gradient Investments LLC | $4.04M | 0.3 | 138,427 | -1.09% | -$44,472.81 | 0.11 | |
| Scout Investments | $4.01M | 0.3 | 137,581 | -5.99% | -$255,470.59 | 0.1 | |
| Clearline Capital LP | $3.99M | 0.29 | 136,658 | -58.69% | -$5.67M | 0.39 |